drugset
drugset / Trial / NCT04727138

3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546

NCT04727138 ↗

Phase 1 Completed 64 enrolled Exscientia AI Limited Quotient Sciences · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

A 3-part Study to Assess Safety, Tolerability, PK and PD of Single (Part 1) and Multiple (Part 2) Ascending Doses of EXS21546, and to Evaluate the Relative Bioavailability of a Solid Dose Formulation Compared to a Powder for Oral Suspension (Part 3), in Healthy Male Subjects.

Timeline

Start
2020-12-08
Primary completion
2022-04-16
Completion
2022-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EXS21546 Unknown — Oral

Indications

No indication recorded.